Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of ZGN-1061 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus to Evaluate Glycemic Control, Safety, and Tolerability Over 12 Weeks
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Aclimostat (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Zafgen
- 11 Jun 2019 Results presented at the 79th Annual Scientific Sessions of the American Diabetes Association.
- 11 Jun 2019 Results of a phase 2 trial assessing efficacy of ZGN-1061 in patients with type 2 diabetes presented at the 79th Annual Scientific Sessions of the American Diabetes Association
- 10 Jun 2019 Results presented in a Zafgen Media Release.